Findings

What do systematic reviews say?

1,163 questions · 1,209 findings · 133 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 176 · 14.6%GRADE not reported 47 · 3.9%Very low 241 · 19.9%Low 323 · 26.7%Moderate 315 · 26.1%High 107 · 8.9%

Reslizumab intravenous (IV) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Reslizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Rate ratio 0.43 [0.33, 0.55]
2 studies · 953 participants
High

Reslizumab subcutaneous (SC) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Reslizumab subcutaneous (SC) showed no clear difference in rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Rate ratio 0.79 [0.56, 1.11]
1 study · 464 participants
High

Benralizumab subcutaneous (SC) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Benralizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Rate ratio 0.59 [0.52, 0.66]
4 studies · 3112 participants
High

Mepolizumab intravenous (IV) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Mepolizumab intravenous (IV) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Anti‐IL‐5 therapies for asthma 2022 · Cochrane Headline outcomes only
Rate ratio 0.53 [0.44, 0.64]
3 studies · 751 participants
High

Tocilizumab weekly vs placebo + 52‐week taper

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

The review found no eligible studies for this question.

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tocilizumab weekly vs placebo + 26‐week taper

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

The review found no eligible studies for this question.

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tocilizumab every other week vs placebo + 52‐week taper

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

The review found no eligible studies for this question.

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tocilizumab every other week vs placebo + 26‐week taper

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

The review found no eligible studies for this question.

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tocilizumab every 4 weeks vs placebo

Cumulative mean dose of corticosteroids at ≥ 12 months · adults aged over 50 years with giant cell arteritis

1 finding from 1 review

Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 30 participants
Moderate

Summary of findings: complete control of vomiting during the overall phase (HEC) when vs treatment with aprepitant + granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: serious adverse events (HEC) when vs treatment with aprepitant + granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by highly emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: complete control of vomiting during the overall phase (MEC) when vs treatment with granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: serious adverse events (MEC) when vs treatment with granisetron

Interventions (corticosteroids included in all regimens)a · adult cancer patients at risk for CINV caused by moderately emetogenic chemotherapy

The review found no eligible studies for this question.

1 finding from 1 review

Antiemetics for adults for prevention of nausea and vomiting caused by moderately or highly emetogenic chemotherapy: a… 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Corticosteroids · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Corticosteroids · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Corticosteroids · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Corticosteroids · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Corticosteroids · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Corticosteroids · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Corticosteroids · adults undergoing any type of surgery under general anaesthesia Interventions: antiemetic drugs (monoprophylaxis and combination…

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta‐analysis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found